Ironwood Pharmaceuticals (IRWD) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Ironwood Pharmaceuticals is expected to release its Q2 2025 earnings report on August 14th, with analysts predicting earnings of ($0.02) per share and $62.02 million in revenue.
• In the last quarter, Ironwood reported a loss of ($0.14) EPS, falling short of the expected ($0.05), with actual revenue of $41.14 million, significantly below analyst estimates of $67.02 million.
• Hedge funds have substantially increased their holdings in Ironwood, with Millennium Management increasing its stake by 186.6% during the first quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Ironwood Pharmaceuticals to post earnings of ($0.02) per share and revenue of $62.02 million for the quarter. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.16. The firm had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 2.25%. On average, analysts expect Ironwood Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Up 1.9%

IRWD stock traded up $0.02 during trading on Friday, hitting $0.90. 1,015,972 shares of the company's stock were exchanged, compared to its average volume of 1,398,655. The business has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $1.17. The stock has a market capitalization of $145.14 million, a price-to-earnings ratio of -17.93 and a beta of 0.33. Ironwood Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $5.21.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on IRWD shares. Leerink Partners decreased their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research note on Monday, April 14th. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Citizens Jmp lowered Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday, April 14th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $1.00 price target (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $4.94.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 535.8% in the first quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company's stock valued at $3,710,000 after buying an additional 2,126,889 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock valued at $9,349,000 after buying an additional 4,140,439 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $57,000. Goldman Sachs Group Inc. boosted its position in Ironwood Pharmaceuticals by 72.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company's stock worth $2,316,000 after purchasing an additional 660,144 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.